Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Brain Imaging01:14

Brain Imaging

480
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
480
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Amyloid Fibrils03:03

Amyloid Fibrils

6.1K
6.1K
Amyloid Fibrils03:03

Amyloid Fibrils

11.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Impact of plasma pTau181 levels on clinician diagnostic confidence and management in memory and cognition clinics: A multi-site before-and-after study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Analysis of second-generation epigenetic clocks reveals further associations between disproportionate biological ageing and hippocampal volume.

GeroScience·2026
Same author

Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.

EBioMedicine·2026
Same author

Toxoplasma gondii infection is associated with changes in chronic outcomes in traumatic brain injury.

Translational psychiatry·2026
Same author

Evidence for direct and sleep-moderated relationships between aquaporin-4 genetic variants and Alzheimer's disease phenotypes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
Same journal

Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.

Seminars in nuclear medicine·2026
See all related articles

Related Experiment Video

Updated: Nov 20, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

548

Advances in Brain Amyloid Imaging.

Natasha Krishnadas1, Victor L Villemagne2, Vincent Doré3

  • 1Florey Department of Neurosciences and Mental Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Victoria, Australia; Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia.

Seminars in Nuclear Medicine
|January 23, 2021
PubMed
Summary
This summary is machine-generated.

Amyloid-beta (Aβ) PET imaging offers reliable in vivo detection of Aβ burden, aiding Alzheimer

More Related Videos

Visualization of Amyloid &#946; Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

10.9K
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.3K

Related Experiment Videos

Last Updated: Nov 20, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

548
Visualization of Amyloid &#946; Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

10.9K
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.3K

Area of Science:

  • Neuroimaging
  • Nuclear Medicine
  • Alzheimer's Disease Research

Background:

  • Amyloid-beta (Aβ) Positron Emission Tomography (PET) imaging has been a clinical and research tool for over 15 years.
  • Aβ imaging provides accurate and reproducible measurements of Aβ burden in the brain, crucial for understanding neurodegenerative diseases.
  • Its utility spans clinical diagnosis, differentiating Alzheimer's disease (AD) from other conditions, and guiding therapeutic interventions.

Purpose of the Study:

  • To review the current landscape of Aβ PET imaging, including available radiotracers and quantification methods.
  • To discuss the clinical and research applications of Aβ PET in Alzheimer's disease.
  • To highlight advancements and ongoing challenges in Aβ PET standardization and application.

Main Methods:

  • Review of available Amyloid-beta (Aβ) radiotracers for Positron Emission Tomography (PET).
  • Discussion of quantification approaches, including the Centiloid method for standardization.
  • Analysis of clinical and research applications, including diagnostic use and therapy trials.

Main Results:

  • Aβ PET is a powerful diagnostic tool, improving Alzheimer's disease (AD) diagnosis accuracy when combined with clinical evaluation.
  • It is invaluable in anti-Aβ therapy trials, facilitating the development of disease-modifying treatments and enabling trials in preclinical AD.
  • The Centiloid method offers standardized quantification, correlating with neuropathology and prognosis, with automated analysis now feasible.

Conclusions:

  • Aβ PET imaging significantly enhances the diagnosis and management of Alzheimer's disease (AD) and related disorders.
  • Its role in clinical trials is pivotal for developing effective anti-Aβ therapies, with disease-modifying treatments on the horizon.
  • Continued standardization and addressing technical challenges will further optimize Aβ PET's clinical and research impact.